📚 Lecture Overview
This lecture explores the chronic complications of diabetes mellitus, classifying them into macrovascular, microvascular, and other pathologic changes. Understanding these late manifestations is crucial because they drive major morbidity and mortality, including end-stage renal disease, blindness, neuropathy, and myocardial infarction.
🎯 Key Concepts & Definitions
- Macrovascular Complications: Large vessel diseases such as coronary atherosclerosis, peripheral vascular disease, and cerebrovascular accidents leading to myocardial infarction and stroke.
- Microvascular Complications: Small vessel pathologies affecting the eyes (retinopathy, cataracts), kidneys (nephropathy), and nerves (neuropathy).
- Non-proliferative Retinopathy: Early stage of retinal involvement characterized by capillary leakage, microaneurysms, retinal hemorrhages, and macular edema.
- Proliferative Retinopathy: Advanced retinal involvement featuring the growth of new capillaries (neovascularization) and fibrosis, leading to vitreous hemorrhage and retinal detachment.
- Microalbuminuria: An albumin-creatinine ratio of 30-300 mcg/mg in early morning spot urine, serving as the earliest clinical sign of diabetic nephropathy.
- Distal Symmetric Polyneuropathy: The most common form of peripheral neuropathy, presenting in a stocking-glove pattern with sensory loss and delayed nerve conduction.
- Diabetic Amyotrophy: An isolated peripheral neuropathy presenting with severe front-of-thigh pain followed by quadriceps weakness and wasting.
- Gastroparesis: Autonomic neuropathy of the gastrointestinal system causing unexpected postprandial glucose fluctuations, nausea, and vomiting.
📖 Main Content
1. Ocular Complications
- Diabetic chronic hyperglycemia causes premature cataracts via nonenzymatic glycosylation of lens proteins.
- Diabetic retinopathy is the leading cause of adult blindness (ages 20-65) and increases in prevalence with duration and poor control.
- Macular involvement is the most common cause of blindness.
- Screening: Type 1 patients are screened 5 years post-diagnosis; Type 2 patients are screened at diagnosis.
- Treatment & Management:
- Glycemic control is the most important modifiable factor.
- VEGF inhibitors (ranibizumab, bevacizumab) and pan-retinal laser photocoagulation are mainstays for proliferative retinopathy and macular edema.
2. Diabetic Nephropathy
- Initially presents as hyperfiltration (increased GFR) followed by microalbuminuria.
- Diagnosed via an early morning spot urine albumin-creatinine ratio (30-300 mcg/mg) confirmed across multiple collections.
- Progression: Advances to overt proteinuria (>300 mg/day) and eventual End-Stage Renal Disease (ESRD).
- Treatment & Management:
- Strict blood pressure goal of 130/80 mm Hg or less.
- ACE inhibitors or ARBs reduce intraglomerular pressure and slow progression to ESRD (monitor for hyperkalemia).
- SGLT2 inhibitors slow nephropathy progression and offer cardiorenal protection.
3. Diabetic Neuropathy
- Affects up to 50% of diabetes patients.
- Peripheral Neuropathy:
- Distal Symmetric Polyneuropathy: Stocking-glove sensory loss, burning pain, and lost ankle jerks.
- Isolated Neuropathy (Mononeuropathy): Sudden onset involving single cranial or femoral nerves (e.g., diplopia, diabetic amyotrophy) with eventual recovery.
- Autonomic Neuropathy: Affects visceral functions including the GI system (gastroparesis), genitourinary system (atonic bladder, erectile dysfunction), and orthostatic hypotension.
- Pharmacologic Treatment for Pain:
- Pregabalin, duloxetine, or gabapentin are recommended as initial treatments.
- Additional options include tricyclic antidepressants (amitriptyline, nortriptyline), topical capsaicin, and 5% lidocaine patches.
4. Cardiovascular & Peripheral Vascular Complications
- Heart Disease: Myocardial infarction is 3-5 times more common in diabetic patients and is the leading cause of death in Type 2 diabetes. Diabetes is considered a coronary risk equivalent.
- Lipid Management: Target LDL cholesterol < 100 mg/dL, or < 70 mg/dL for patients with multiple cardiovascular risk factors.
- Hypertension: Target blood pressure is 130/80 mm Hg or less, managed with ACE inhibitors or ARBs if microalbuminuria or cardiovascular disease is present.
- Peripheral Vascular Disease: Accelerated atherosclerosis leads to lower extremity ischemia and high risk of gangrene.
- Avoid agents that reduce peripheral blood flow like tobacco.
- Beta-blockers are relatively contraindicated due to negative peripheral hemodynamic consequences.
- Statins are useful for dyslipidemia and early ischemic signs.
📊 Visual Learning
💡 Important Points to Remember
- Mortality Causes: End-stage chronic kidney disease is a major cause of death in Type 1 diabetes, while macrovascular disease (myocardial infarction and stroke) is the main cause of death in Type 2 diabetes.
- Retinopathy Screening: Screen Type 1 patients 5 years after diagnosis; screen Type 2 patients at or shortly after diagnosis.
- Macular Edema: Macular involvement is the most common cause of blindness and visual impairment in diabetic retinopathy.
- Nephropathy Screening: Yearly screening using an early morning spot albumin-creatinine ratio (30-300 mcg/mg) is vital for detecting microalbuminuria.
- Renal Protection: ACE inhibitors or ARBs reduce intraglomerular pressure, but clinicians must monitor closely for hyperkalemia and GFR drops >30%.
- Medication Contraindication: Beta-blockers are relatively contraindicated in peripheral vascular disease due to negative peripheral hemodynamic consequences.
- Neuropathy First-Line Drugs: Pregabalin, duloxetine, and gabapentin are primary agents used to treat painful diabetic peripheral neuropathy.
- Cigarette Smoking: Cigarette use significantly compounds the risk for both microvascular and macrovascular complications and must be avoided.
- Cardiovascular Equivalence: Diabetes is designated as a coronary risk equivalent, making strict LDL control (<100 mg/dL or <70 mg/dL) mandatory.
⚠️ Common Exam Questions
Examiners frequently test the following trap scenarios:
- Timing Traps in Retinopathy: Confusing screening timelines for Type 1 (5 years post-diagnosis) versus Type 2 (at diagnosis).
- Combination RAS Inhibition Trap: Suggesting combination therapy of an ACE inhibitor and an ARB; examiners use this to test if students know it causes high rates of hyperkalemia without added clinical efficacy.
- Beta-Blocker Trap: Recommending beta-blockers for hypertension in a patient with severe peripheral vascular disease; examiners test whether you know beta-blockers are relatively contraindicated due to worsening peripheral ischemia.
- Cause of Death Mix-ups: Reversing the primary causes of death between Type 1 (renal disease) and Type 2 (macrovascular/MI/stroke) diabetes.
📝 Quick Review Checklist
I can classify chronic diabetic complications into macrovascular, microvascular, and other categories
I understand the pathogenesis and stages of diabetic retinopathy and when to screen
I can define microalbuminuria and explain the management of diabetic nephropathy using ACE inhibitors/ARBs
I know how to differentiate distal symmetric polyneuropathy from isolated neuropathies and autonomic manifestations
I understand the cardiovascular risks associated with diabetes and target goals for LDL and blood pressure